Fengwei Li
Impact in
- Cancer Research top 10%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Cancer, Lipids, and Metabolism
Papers in
-
- MicroRNA in disease regulation 4
- Cancer-related molecular mechanisms research 3
- Cancer, Lipids, and Metabolism 2
- Surgery 8
- Cholangiocarcinoma and Gallbladder Cancer Studies 7
- Co-authors
- Qinjunjie Chen (5 shared papers)Kui Wang (8 shared papers)Leilei Liang (2 shared papers)Feng Shen (5 shared papers)Yong Xia (5 shared papers)Yiran Zou (2 shared papers)Zheng Li (2 shared papers)Jun Li (1 shared paper)
- Journals
- Frontiers in Oncology (2 papers)Cell Metabolism (1 paper)Journal of Cancer (1 paper)BMJ Open (1 paper)Journal of Hepatology (1 paper)
- Partner nations
- ChinaHong KongUnited States
In The Last Decade
Fengwei Li
22 papers receiving 497 citations
Hit Papers
Peers
Comparison fields: 5 of 89
- Cancer Research 211
- Hepatology 45
- Molecular Biology 280
- Health, Toxicology and Mutagenesis 44
- Immunology 55
Countries citing papers authored by Fengwei Li
This map shows the geographic impact of Fengwei Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fengwei Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fengwei Li more than expected).
Fields of papers citing papers by Fengwei Li
This network shows the impact of papers produced by Fengwei Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fengwei Li. The network helps show where Fengwei Li may publish in the future.
Co-authors
The 25 scholars most cited alongside Fengwei Li, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Circular RNA ACTN4 promotes intrahepatic cholangiocarcinoma progression by recruiting YBX1 to initiate FZD7 transcription Hit paper breakdown → | 2021 | 171 |
| 2 | 2020 | 57 | |
| 3 | 2021 | 39 | |
| 4 | 2020 | 37 | |
| 5 | 2022 | 31 | |
| 6 | 2020 | 30 | |
| 7 | 2020 | 25 | |
| 8 | 2021 | 24 | |
| 9 | 2023 | 14 | |
| 10 | 2023 | 12 | |
| 11 | 2020 | 12 | |
| 12 | 2024 | 12 | |
| 13 | 2015 | 12 | |
| 14 | 2020 | 10 | |
| 15 | 2018 | 7 | |
| 16 | 2022 | 5 | |
| 17 | 2024 | 4 | |
| 18 | 2023 | 4 | |
| 19 | 2017 | 3 | |
| 20 | 2021 | 3 |
About Fengwei Li
Fengwei Li is a scholar working on Cancer Research, Surgery, Molecular Biology, Pulmonary and Respiratory Medicine and Epidemiology, having authored 24 papers that have together received 514 indexed citations. Recurring topics across this work include Cholangiocarcinoma and Gallbladder Cancer Studies (7 papers), MicroRNA in disease regulation (4 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers), Cancer-related molecular mechanisms research (3 papers), Lung Cancer Diagnosis and Treatment (3 papers), RNA modifications and cancer (3 papers), Medical Imaging and Pathology Studies (2 papers) and Cancer, Lipids, and Metabolism (2 papers). The work is most often cited by research in Cancer Research (211 citations), Hepatology (45 citations), Molecular Biology (280 citations), Health, Toxicology and Mutagenesis (44 citations) and Immunology (55 citations). Fengwei Li has collaborated with scholars based in China, Hong Kong and United States. Frequent co-authors include Qinjunjie Chen, Kui Wang, Leilei Liang, Feng Shen, Yong Xia, Yiran Zou, Zheng Li, Jun Li, Tian Yang and Hao Shen. Their work appears in journals such as Frontiers in Oncology, Cell Metabolism, Journal of Cancer, BMJ Open and Journal of Hepatology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.